

Santaris Pharma

Copenhagen, 25th May 2007

Dr Flemming Ørnskov appointed Chairman of Santaris Pharma Board

Santaris Pharma, the Danish biopharmaceutical company, announced today that Dr Flemming Ørnskov, Chief Executive Officer of Lifecycle Pharma A/S, has been elected non-executive Chairman of Santaris Pharma A/S. Dr Ørnskov takes over responsibilities from Santaris Pharma's current Chairman, Martien van Osch, a general partner at Forbion Capital Partners, with immediate effect. Dr Ørnskov was appointed to the Santaris Pharma Board by shareholders at the Company's Annual General Meeting on 24th May 2007 and elected Chairman by the Santaris Pharma Board immediately thereafter.

Announcing the appointment, Dr Keith McCullagh, President and CEO of Santaris Pharma, said:

"I am pleased to welcome Flemming Ørnskov to Santaris as the new Chairman of the Company's Board of Directors. He brings outstanding qualities of leadership and entrepreneurship to Santaris from the international pharmaceutical and biotech industry. I look forward to working in partnership with him and other members of the Board as we seek to build a competitive 21st century biopharmaceutical business. I also warmly thank Martien van Osch from Forbion Capital Partners, who has chaired the Santaris Board over the past year. He has brought high quality judgement and collegiate leadership to Board decisions and made a significant contribution to the Company's progress. I am delighted that Martien will continue to serve as a member of the Board."

Commenting on Santaris Pharma and his appointment, Dr Ørnskov said:

"Santaris Pharma is a company at the forefront of modern molecular medicine. Its unique RNA Antagonist drug portfolio, now at a critical stage of pharmaceutical development, has the potential to transform patient outcomes across a range of serious human diseases. I am pleased to have the opportunity to contribute to the Company's growth and future success"